Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Respiratory Medicine

Journal Scan / Research · July 04, 2023

Safety, Tolerability, and Health-Related Quality-of-Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC

Journal of Thoracic Oncology

 

Additional Info

Journal of Thoracic Oncology
Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial
J Thorac Oncol 2023 May 23;[EPub Ahead of Print], T John, C Grohé, JW Goldman, FA Shepherd, F de Marinis, T Kato, Q Wang, WC Su, JH Choi, V Sriuranpong, B Melotti, MJ Fidler, J Chen, M Albayaty, M Stachowiak, S Taggart, YL Wu, M Tsuboi, RS Herbst, M Majem

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading